Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS41003 for Super-infected Eczema
NCT01020994Phase 2Completed
- Sponsor
- Almirall
- Start
- Nov 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prednicarbate + octenidine in Eczema (3 arms), sponsored by Almirall. Primary endpoint: Combination of clinical and microbial treatment success at 14 days. Started Nov 2009; status: completed.
02
Drugs
prednicarbate + octenidine
03
Conditions
Eczema
Beyond the preview
Go deeper on NCT01020994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01020994.